prostate cancer
Conditions
Interventions
Patients received 70Gy/28fxs to the prostate and the base of the seminal vesicle with IMRT.
Sponsors
Department of Radiation Oncology, The Cancer Institute Hospita, the Japanese Fundation for Cancer Reseach
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1)Histologically confirmed prostate adenocarcinoma 2)One of the following combinations of factors: - Clinical stage T1b-2cN0M0, Gleason score 2-6, and prostate-specific antigen >10 but <20; - Clinical stage T1b-T2cN0M0, Gleason score 7, and prostate-specific antigen <20 3)ECOG-PS 0-1 4)No previous hormonal therapy or within 10 months after the start of hormonal therapy 5)Calcification in the prostate recognized on CT scans 6)Patients must sign informed consent form prior to registration
Exclusion criteria
Exclusion criteria: 1) Small cell carcinoma 2) Previous or concurrent invasive cancers 3) Previous pelvic irradiation 4) Previous orchiectomy 5) Previous treatment of prostate cancer other than hormonal therapy 6) Cases judged by their physicians to be inappropriate as subjects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of late adverse effects at three years | — |
Countries
Japan
Contacts
Public ContactTakuyo Kozuka M.D., Ph.D.
The Cancer Institute Hospital, Japanese Foundation for Cancer Research Department of Radiation Oncology
Outcome results
None listed